ANAB icon

AnaptysBio

32.46 USD
+1.09
3.47%
At close Updated Oct 13, 4:00 PM EDT
Pre-market
After hours
32.46
0.00
0%
1 day
3.47%
5 days
3.67%
1 month
61.01%
3 months
20.45%
6 months
81.75%
Year to date
142.96%
1 year
-6.56%
5 years
82.77%
10 years
90.94%
 

About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Employees: 136

0
Funds holding %
of 7,491 funds
0
Analysts bullish %
of 5 analysts
0
Positive news %
of 5 articles
Price charts implemented using Lightweight Charts™